My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 8 485 / DOI: 10.3332/ecancer.2014.485

Clinical Study

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.

Keywords: Drug repurposing, cimetidine, immunostimulant, ReDO project

Loading Article Metrics ... Please wait

Related articles

Conference Report: Highlights from the first International ecancer Conference on Oncology and Radiotherapy, 6–7 May 2016, Santiago, Chile

Abstract | Full Article | PDF | Spanish Published: 22 Jul 2016 / DOI: 10.3332/ecancer.2016.658

Special Issue: Integration of legal aspects and human rights approach in palliative care delivery—The Nyeri hospice model

Abstract | Full Article | PDF Published: 07 Jul 2016 / DOI: 10.3332/ecancer.2016.656

Special Issue: The Island Hospice model of palliative care

Abstract | Full Article | PDF Published: 07 Jul 2016 / DOI: 10.3332/ecancer.2016.654

Special Issue: Interventions geared towards strengthening the health system of Namibia through the integration of palliative care

Abstract | Full Article | PDF Published: 07 Jul 2016 / DOI: 10.3332/ecancer.2016.653

Special Issue: Best practices in developing a national palliative care policy in resource limited settings: lessons from five African countries

Abstract | Full Article | PDF Published: 07 Jul 2016 / DOI: 10.3332/ecancer.2016.652



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence